Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
Clinical trial NCT03581292 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03581292
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-06
- Primary completion
- 2023-03-31
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.